We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Barr Pharmaceuticals will have to wait until May to get an FDA decision on whether the firm’s emergency contraceptive Plan B (synthetic progestin levonorgestrel) will receive OTC status.